Recombinant Human Activin RIIA Protein

COA

级别和纯度:

≥95%(SDS-PAGE)

表达系统: HEK293
Accession #: P27037-1
蛋白标签: C-His
生物活性: Measured by its ability to inhibit Activin A-induced hemoglobin expression in K562 human chronic myelogenous leukemia cells. Approximately 0.01-0.05 μg/mL of Recombinant Human (rh) Activin RIIA Fc Chimera will inhibit 50% of the biological response due to 3 ng/mL of rhActivin A.
内毒素水平: <0.1 EU/μg

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
rp142510-10μg	10μg	现货
rp142510-50μg	50μg	现货
rp142510-100μg	100μg	现货
rp142510-1mg	1mg	期货

查看相关系列

点击查看蛋白信息: ACVR2A

Accession#: P27037 (3) Activin Receptor Type IIA (2) Activin RIIA (3) Acvr2a (4) Gene ID: 92 (3)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本描述

产品名称	Recombinant Human Activin RIIA Protein
别名	激活素A受体ⅡA(ACVR2A)重组蛋白 \| 重组人类激活素 RIIA 蛋白
英文别名	Activin receptor type IIA \| ACTRIIA \| ACTR-IIA \| EC 2.7.11.30 \| Activin A receptor type IIA \| Activin receptor type 2A \| Activin receptor type IIA \| Activin receptor type-2A \| ACTR 2 \| ACTR IIA \| ACTR-IIA \| ACTR2 \| ACTRII \| ACTRIIA \| Acvr 2A \| Acvr 2 \| Ac
规格或纯度	ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, High performance, ≥95%(SDS-PAGE)
产品介绍	Purity ≥95% (SDS-PAGE) Endotoxin level ＜0.1 EU/μg Function On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin A, activin B and inhibin A.
生物活性	Measured by its ability to inhibit Activin A-induced hemoglobin expression in K562 human chronic myelogenous leukemia cells. Approximately 0.01-0.05 μg/mL of Recombinant Human (rh) Activin RIIA Fc Chimera will inhibit 50% of the biological response due to 3 ng/mL of rhActivin A.
内毒素水平	<0.1 EU/μg
表达系统	HEK293
种属	人(Human)
氨基酸	20-134 aa
序列	AILGRSETQECLFFNANWEKDRTNQTGVEPCYGDKDKRRHCFATWKNISGSIEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSNPVTPKPHHHHHH
纯度	≥95% (SDS-PAGE)
蛋白标签	C-His
无载体	Yes
无动物源	Yes
Accession #	P27037-1
来源	重组表达
预测分子量	13 kDa
SDS-PAGE	30.0 - 35.0 kDa, under reducing conditions; 30.0 - 35.0 kDa, under non-reducing conditions.

储存与运输

物理形态	冻干(Lyophilized)
储存缓冲液	Lyophilized from 10mM PBS, 5% Trehalose, 5% Mannitol, pH 7.4
复溶	Reconstitute in sterile water to a concentration of 0.1-0.5 mg/ml.
储存温度	-20°C储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -20~-80℃ 下可保存 1 年以上。收货后建议分装。避免冷冻/解冻循环。
分子类型	蛋白质

图片

SDS-PAGE: Recombinant Human Activin RIIA Protein (rp142510)

Recombinant Human Activin RIIA Protein (rp142510) - SDS-PAGE
3 μg/lane of Recombinant Human Activin RIIA Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing the band at 30.0 - 35.0 kDa.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到3个结果

批号(Lot Number)	证书类型	货号
ZJ24F0606777	分析证书	rp142510
ZJ24F0606775	分析证书	rp142510
ZJ24F0606776	分析证书	rp142510

技术文档和文章

引用文献

1. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C et al.. (2007) Patterns of somatic mutation in human cancer genomes.. Nature, 446 (7132): (153-8). [PMID:17344846]
2. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q et al.. (2009) AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).. Blood, 114 (14): (2984-92). [PMID:19654408]
3. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P.. (2008) Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.. J Med Chem, 51 (21): (6642-6645). [PMID:18834107] [10.1021/jm800986w]
4. Deng X, Lim SM, Zhang J, Gray NS.. (2010) Broad spectrum alkynyl inhibitors of T315I Bcr-Abl.. Bioorg Med Chem Lett, 20 (14): (4196-4200). [PMID:20541934] [10.1016/j.bmcl.2010.05.043]
5. Sunose M, Bell K, Ellard K, Bergamini G, Neubauer G, Werner T, Ramsden N.. (2012) Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.. Bioorg Med Chem Lett, 22 (14): (4613-4618). [PMID:22726925] [10.1016/j.bmcl.2012.05.090]
6. Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR, Gray NS.. (2012) GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.. Bioorg Med Chem Lett, 22 (17): (5625-5629). [PMID:22863203] [10.1016/j.bmcl.2012.06.104]
7. Malki WH, Gouda AM, Ali HEA, Al-Rousan R, Samaha D, Abdalla AN, Bustamante J, Abd Elmageed ZY, Ali HI.. (2018) Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition.. Eur J Med Chem, 152 (31-52). [PMID:29684708] [10.1016/j.ejmech.2018.04.029]
8. Wang Q, Liu F, Qi S, Qi Z, Yan XE, Wang B, Wang A, Wang W, Chen C, Liu X, Jiang Z, Hu Z, Wang L, Wang W, Ren T, Zhang S, Yun CH, Liu Q, Liu J.. (2018) Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.. Eur J Med Chem, 150 (366-384). [PMID:29544149] [10.1016/j.ejmech.2018.03.003]
9. Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.. (2018) Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.. Bioorg Med Chem Lett, 28 (20): (3356-3362). [PMID:30227946] [10.1016/j.bmcl.2018.09.006]
10. Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A, Wu H, Hu Z, Jiang Z, Liu Q, Wang W, Zhang Y, Liu F, Zhao M, Hu J, Huang T, Ge J, Wang L, Ren T, Wang Y, Liu J, Liu Q.. (2018) Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.. Eur J Med Chem, 158 (896-916). [PMID:30253346] [10.1016/j.ejmech.2018.09.025]
11. Dodo K, Kuboki E, Shimizu T, Imamura R, Magarisawa M, Takahashi M, Tokuhiro T, Yotsumoto S, Asano K, Nakao S, Terayama N, Suda T, Tanaka M, Sodeoka M.. (2019) Development of a Water-Soluble Indolylmaleimide Derivative IM-93 Showing Dual Inhibition of Ferroptosis and NETosis.. ACS Med Chem Lett, 10 (9): (1272-1278). [PMID:31531196] [10.1021/acsmedchemlett.9b00142]
12. Zhang Q, Hu X, Wan G, Wang J, Li L, Wu X, Liu Z, Yu L.. (2019) Discovery of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer.. Eur J Med Chem, 184 (111728-111728). [PMID:31610375] [10.1016/j.ejmech.2019.111728]
13. Wang Y, Dou X, Jiang L, Jin H, Zhang L, Zhang L, Liu Z.. (2019) Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.. Eur J Med Chem, 171 (221-234). [PMID:30925338] [10.1016/j.ejmech.2019.03.039]
14. Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS.. (2017) Discovery of a potent dual ALK and EGFR T790M inhibitor.. Eur J Med Chem, 136 (497-510). [PMID:28528303] [10.1016/j.ejmech.2017.04.079]
15. Oukoloff K, Coquelle N, Bartolini M, Naldi M, Le Guevel R, Bach S, Josselin B, Ruchaud S, Catto M, Pisani L, Denora N, Iacobazzi RM, Silman I, Sussman JL, Buron F, Colletier JP, Jean L, Routier S, Renard PY.. (2019) Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3.. Eur J Med Chem, 168 (58-77). [PMID:30798053] [10.1016/j.ejmech.2018.12.063]
16. Matzuk, M M MM and Bradley, A A.. (1992) Cloning of the human activin receptor cDNA reveals high evolutionary conservation.. Biochimica et biophysica acta, (28): [PMID:1311955]
17. Donaldson, C J CJ, Mathews, L S LS and Vale, W W WW.. (1992) Molecular cloning and binding properties of the human type II activin receptor.. Biochemical and biophysical research communications, (15): [PMID:1314589]
18. Greenwald, Jason J and 6 more authors.. (2003) The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly.. Molecular cell, [PMID:12667445]
19. Varela, Ignacio I and 43 more authors.. (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.. Nature, (27): [PMID:21248752]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度